ASX:ATX

Amplia Therapeutics Stock Forecast, Price & News

Add

Compare

Today's Range N/A

50-Day Range N/A

52-Week Range N/A

Volume77,249 shs

Average VolumeN/A

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Receive ATX News and Ratings via Email

Sign-up to receive the latest news and ratings for Amplia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Amplia Therapeutics

Amplia Therapeutics Limited, a pharmaceutical company, focuses on advancing a pipeline of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. The company's clinical development pipeline comprises two lead molecules, AMP945 and AMP886 that inhibits (FAK). It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.

What Percentage Of Amplia Therapeutics Limited (ASX:ATX) Shares Do Insiders Own?
November 11, 2019 | finance.yahoo.com

Should You Worry About Amplia Therapeutics Limited's (ASX:ATX) CEO Pay?
November 11, 2019 | finance.yahoo.com

Do Directors Own Amplia Therapeutics Limited (ASX:ATX) Shares?
November 11, 2019 | finance.yahoo.com

Rep. Chris Collins expected to plead guilty to insider trading: reports
November 11, 2019 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange: ASX
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: ASX:ATX
Previous Symbol
CUSIP: N/A
CIK: N/A
Web: www.ampliatx.com
Phone: 61 2 8003 3650
Employees: N/A
Year Founded: N/A

Sales & Book Value

Annual Sales: $1.53 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 4.88
Book Value: A$0.10 per share
Price / Book: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Net Income: N/A
Net Margins: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.45
Quick Ratio: 5.28

Price-To-Earnings

Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A

Miscellaneous

Outstanding Shares: N/A
Market Cap: N/A
Next Earnings Date: N/A
Optionable: Not Optionable

MarketRank^™

Overall MarketRank^™

1.33 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Amplia Therapeutics.

5.0 Community Rank

Outperform Votes
Amplia Therapeutics has received 9 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Amplia Therapeutics has received 1 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Amplia Therapeutics has received 90.00% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Amplia Therapeutics and other stocks. Vote “Outperform” if you believe ATX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ATX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Amplia Therapeutics does not currently pay a dividend.
Dividend Growth
Amplia Therapeutics does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Amplia Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought A$115,433.00 in company stock and sold A$0.00 in company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

Amplia Therapeutics (ASX:ATX) Frequently Asked Questions

What stocks does MarketBeat like better than Amplia Therapeutics?: Wall Street analysts have given Amplia Therapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Amplia Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.
Who are Amplia Therapeutics' key executives?: Amplia Therapeutics' management team includes the following people:
Dr. John Lambert B.Sc., BSc (Hons), MRACI, C.Chem., Ph.D., CEO, MD & Director (Age 56, Pay $174.13k)
Mr. Jeff Carter, Chief Financial Officer (Age 63, Pay $90.3k)
Mr. Andrew John Cooke LLB, FAICS, MAICD, FGIA, FCIS, Company Sec. (Age 61, Pay $76.67k)
Dr. Mark Devlin B.Sc., Ph.D., Chief Scientific Officer
Dr. Frank Gelder, Founding Scientist
Dr. James A. Taylor, Trials Consultant (Age 60)
Dr. Michael H. Silverman B.Sc., M.B.A., M.D., F.A.C.P., FACR, Trials Consultant (Age 73)
Dr. Benjamin M. Segal, Clinical Consultant
Dr. Frederick E. Reno, Toxicology Consultant
Who are some of Amplia Therapeutics' key competitors?: Some companies that are related to Amplia Therapeutics include (TNGN) (TNGN), 3SBio (TRSBF), 45525 (CUR.TO) (CUR), Abattis Bioceuticals (ATTBF), Abzena (ABZA), Acrux (ACR), Actinogen Medical (ACW), AdAlta (1AD), Admedus (AHZ), Algernon Pharmaceuticals (AGNPF), Almirall (LBTSF), Amarantus BioScience (AMBS), Anatara Lifesciences (ANR), Annovis Bio (ANVS) and Arno Therapeutics (ARNI).
View all of ATX's competitors.
What is Amplia Therapeutics' stock symbol?: Amplia Therapeutics trades on the ASX under the ticker symbol "ATX."
How much money does Amplia Therapeutics make?: Amplia Therapeutics has a market capitalization of $0.00 and generates $1.53 million in revenue each year.
What is Amplia Therapeutics' official website?: The official website for Amplia Therapeutics is www.ampliatx.com.
How can I contact Amplia Therapeutics?: The company can be reached via phone at 61 2 8003 3650.

This page was last updated on 10/26/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms

Your Ultimate Investing Toolkit

Just $1.00 for your first month.